Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Chronic Myeloid Leukaemia

ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML)

Bone Marrow Transplantation volume 32, pages 355–361 (2003)Cite this article

Summary:

Matched unrelated donor transplants have an increased risk of severe graft-versus-host disease and transplant-related mortality (TRM). ATG has been introduced to decrease GvHD and to facilitate engraftment. We conducted a retrospective analysis of 333 patients with chronic myelogenous leukemia, who were treated with Fresenius ATG (n=145, average=90 mg/kg bw, range 40–90 mg/kg bw) or standard immunosuppression without ATG (n=188). Both groups were comparable regarding distribution of age, sex, HLA-matched vs mismatched donors. ATG Fresenius led to a faster leukocyte engraftment, decreased the incidence of acute GvHD and TRM (P=0.01 and P=0.03) and led to a significant better overall survival (70 vs 57%, P=0.03). We concluded that a prospective randomized study is needed to evaluate the definite role of ATG in hemopoietic stem cell transplantation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Thomas ED, Clift RA, Fefer A et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155–163.

    Article  CAS  PubMed  Google Scholar 

  2. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.

    Article  CAS  PubMed  Google Scholar 

  3. Anasetti C, Amos D, Beatty PG et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197–204.

    Article  CAS  PubMed  Google Scholar 

  4. Beatty PG, Ash R, Hows JM, McGlave PB . The use of unrelated bone marrow donors in the treatment of patients with chronic myelogenous leukemia: experience of four marrow transplant centers. Bone Marrow Transplant 1989; 4: 287–290.

    CAS  PubMed  Google Scholar 

  5. Hansen JA, Gooley TA, Martin PJ et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962–968.

    Article  CAS  PubMed  Google Scholar 

  6. Mackinnon S, Hows JM, Goldman JM et al. Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors. Exp Hematol 1990; 18: 421–425.

    CAS  PubMed  Google Scholar 

  7. McGlave P, Bartsch G, Anasetti C et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 1993; 81: 543–550.

    CAS  PubMed  Google Scholar 

  8. Nademanee A, Schmidt GM, Parker P et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 1995; 86: 1228–1234.

    CAS  PubMed  Google Scholar 

  9. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593–602.

    Article  CAS  PubMed  Google Scholar 

  10. Petersdorf EW, Hurley C, Dupont S et al. for the US NMDP. Analysis of 328 marrow transplants for the treatment of chronic myeloid leukemia from unrelated donors facilitated by the US National Marrow Donor Program (NMDP): effect of HLA-DRB1 allele disparity on clinical outcome. Blood 1996; 88 (Suppl.) 268a.

    Google Scholar 

  11. Silver RT, Woolf SH, Hehlmann R et al. An evidence-based analysis of the effect of Busulfan, Hydroxyurea, Interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood, 1999; 94: 1517–1536.

    CAS  PubMed  Google Scholar 

  12. Kantarjian HM, Smith TL, O'Brien S et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to Interferon-α therapy. Ann Intern Med 1995; 122: 254–261.

    Article  CAS  PubMed  Google Scholar 

  13. McGlave PB, Shu XQ, Wen W et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program. Blood 2000; 95: 2219–2225.

    CAS  PubMed  Google Scholar 

  14. Young J, Papadopoulos E, Cunningham I et al. T-cell depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Blood 1992; 79: 3380–3387.

    CAS  PubMed  Google Scholar 

  15. Barrett A, Mavroudis D, Tisdale J et al. T-cell depleted bone marrow transplantation and delayed T-cell add-back to control acute GvHD and conserve a graft versus leukemia effect. Bone Marrow Transplant 1998; 21: 543–551.

    Article  CAS  PubMed  Google Scholar 

  16. Drobyski WR, Ash RC, Casper JT et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 1994; 83: 1980–1987.

    CAS  PubMed  Google Scholar 

  17. Zander AR, Zabelina T, Kroeger N et al. Use of five-agent GvHD prevention regimen in recipients of unrelated donor marrow. Bone Marrow Transplant 1999; 23: 889–893.

    Article  CAS  PubMed  Google Scholar 

  18. Kröger N, Zabelina T, Krüger W et al. Anti-thymocyte-globulin as part of the preparative regimen prevents acute and chronic graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors. Ann Hematol 2001; 80: 209–215.

    Article  PubMed  Google Scholar 

  19. Finke J, Bertz H, Schmoor C et al. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti T-cell globulin. Br J Hematol 2000; 11: 303–313.

    Article  Google Scholar 

  20. Petersdorf EW, Gooley TA, Anasetti C et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998; 92: 3515–3520.

    CAS  PubMed  Google Scholar 

  21. Betty PG, Anasetti C, Hansen JA et al. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood 1993; 81: 249–253.

    Google Scholar 

  22. Bodmer JG, Marsh SG, Albert ED et al. Nomenclature for factors of the HLA-system. Hum Immunol 1994; 41: 1–20.

    Article  CAS  PubMed  Google Scholar 

  23. Petersdorf EW, Longton GM, Anasetti C et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 1997; 89: 1818–1823.

    CAS  PubMed  Google Scholar 

  24. Petersdorf EW, Longton GM, Anasetti C et al. Definition of HLA-DQ as a transplantation antigen. Proc Natl Acad Sci USA 1996; 93: 15358–15363.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Petersdorf EW, Longton GM, Anasetti C et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995; 86: 1606–1613.

    CAS  PubMed  Google Scholar 

  26. Kaplan EL, Meier P . Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  27. Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170.

    CAS  PubMed  Google Scholar 

  28. Cox DR . Regression models and life tables. J R Stat Soc 1972; 34: 187–190.

    Google Scholar 

  29. Storb R, Etzioni R, Anasetti C et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941–949.

    CAS  PubMed  Google Scholar 

  30. Horstmann M, Stockschläder M, Krüger W et al. Cyclo-phosphamide/antithymocyte globulin conditioning of patients with severe aplastic anemia for marrow transplantation from HLA-matched siblings: preliminary results. Ann Hematol 1995; 71: 77–81.

    Article  CAS  PubMed  Google Scholar 

  31. Eiermann TH, Lambrecht P, Zander AR . Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients. Bone Marrow Transplant 1999; 23: 779–781.

    Article  CAS  PubMed  Google Scholar 

  32. Eiermann TH, Freitag S, Cortes-Dericks L et al. Jurkat cell-reactive anti-thymocyte globulin assessed ex vivo by flow cytometry persists three weeks in circulation. J Hematother Stem Cell Res 2001; 10: 385–390.

    Article  CAS  PubMed  Google Scholar 

  33. Genestier L, Fournel S, Flacher M et al. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 1998; 91: 2360–2368.

    CAS  PubMed  Google Scholar 

  34. Kröger N, Zabelina T, Krüger W et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br J Haematol 2001; 113: 1060–1071.

    Article  PubMed  Google Scholar 

  35. Trenschel R, Ross S, Jüsing J et al. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBST. Bone Marrow Transplant 2000; 25: 665–672.

    Article  CAS  PubMed  Google Scholar 

  36. Gratwohl A, Hermans J, Niederwieser D et al. Donor recipient sex combination influence transplant related mortality and relapse incidence following HLA-identical sibling blood and marrow transplantation for chronic myeloid leukemia. Hematol J 2001; 2: 363–370.

    Article  CAS  PubMed  Google Scholar 

  37. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041–2050.

    CAS  PubMed  Google Scholar 

  38. Mackinnon S, Papadopoulos E, Carabasi M et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses form graft-versus host disease. Blood 1995; 86: 1261–1268.

    CAS  PubMed  Google Scholar 

  39. Zander AR, Zabelina T, Löliger C et al. Bone Marrow Transplantation from mismatched unrelated donors. In: Berdel WE, Jürgens H, Büchner Th, Ritter J, Kienast J, Vormoor J (eds). Transplantation in Hematology and Oncology II. Springer-Verlag: New York, 2003.

    Google Scholar 

  40. Remberger M, Storer B, Ringdén O, Anasetti C . Post transplant complications: Association between pretransplant thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 2002; 29: 391–397.

    Article  CAS  PubMed  Google Scholar 

  41. Hale G . Alemtuzumab in stem cell transplantation. Med Oncol 2002; 19 (Suppl.) S33–S47.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf, Germany

    A R Zander, N Kröger & T Zabelina

  2. Department of Bone Marrow Transplantation, University Hospital München, Germany

    M Schleuning & H-J Kolb

  3. Department of Medicine, University Hospital Freiburg, Germany

    J Finke & H Bertz

  4. Department of Bone Marrow Transplantation, University Hospital Essen, Germany

    D Beelen, R Trenschel, H D Ottinger & U W Schaefer

  5. German Clinic for Diagnostic, Center of Bone Marrow Transplantation, Wiesbaden, Germany

    R Schwerdtfeger & H Baurmann

  6. Medical Clinic I, University Hospital Dresden, Germany

    M Bornhäuser & G Ehninger

  7. Clinic for Bone Marrow Transplantation, Idar-Oberstein, Germany

    A A Fauser & M Kiehl

  8. Department of Mathematics in Medicine, University Hospital Hamburg-Eppendorf, Germany

    J Berger

Authors
  1. A R Zander
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Kröger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Schleuning
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Finke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Zabelina
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Beelen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Schwerdtfeger
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H Baurmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Bornhäuser
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G Ehninger
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A A Fauser
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M Kiehl
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. R Trenschel
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. H D Ottinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. H Bertz
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. J Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. H-J Kolb
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. U W Schaefer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zander, A., Kröger, N., Schleuning, M. et al. ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). Bone Marrow Transplant 32, 355–361 (2003). https://doi.org/10.1038/sj.bmt.1704157

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704157

Keywords

This article is cited by

Search

Advanced search

Quick links